Diego Bellabarba, M. D.
Diabetes, Obesity, and Cardiovascular Complications Axis
Centre de recherche du CHUS
Centre hospitalier universitaire de Sherbrooke
Department of Medicine | Division of Endocrinology
Faculty of Medicine and Health Sciences
Université de Sherbrooke
Phone | 819 346-1110 ext. 15241
E-Mail | Diego.Bellabarba@usherbrooke.ca
Thyroid cancer: Use of new drugs
Most thyroid cancers respond to BIEE initial treatment with total thyroidectomy and possibly radio ablation with 131 Iodine.
However, 105 of differentiated cancers are resistant to treatment radio monitoring either in the original or late phase.
These cancers are resistant to conventional chemotherapy. Therefore, we have developed other therapies for their treatment. A path that seems promising is the use of tyrosine kinase inhibitors. Some of these products have already been successfully used (Sorafenib, Sunitinib), but their utilization is limited by the large number of side effects.
New compounds have recently been developed, that are effective in lower doses and therefore may have fewer side effects.
- Corriveau S, Pasquier JC, Blouin S, Bellabarba D, Rousseau E. Chronic Levothyroxine and Acute T3 Treatments Enhance the Amplitude and Time Course of Uterine Contractions in Human
- American Journal of Physiology. Endocrinology and Metabolism. 2013, 304(5), E478-85
Know-How & Opportunities for Collaboration
- Mechanism of action of intracellular hormone
- Technical preparations of cell fractions
- Measurement of DNA
- Technical electrophoresis and buverdage
- Other general laboratory techniques
- Clinical expertise for follow-up of patients enrolled in clinical studies or protocols for new drugs for the treatment of diabetes